A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
A total of 458 eligible patients, from 21 centres, with microscopically confirmed SCLC were allocated at random to three chemotherapy regimens, each given at 3-week intervals. In two regimens, etoposide, cyclophosphamide, methotrexate and vincristine were given for a total of either three courses (E...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
1993
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968653/ |